StemCells, Inc. Announces Strategic Realignment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
- Citi cuts investment banking analyst program to two years - Bloomberg
- Alaska LNG shipping savings justifies billions in investment, developer says
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
StemCells (STEM) PT Cut to $3 at Maxim Group
December 23, 2015 12:18 PM ESTMaxim Group analyst Jason Kolbert lowered his price target on StemCells (NASDAQ: STEM) to $3.00 (from $5.00) but maintained a Buy rating after the company suspended the phase II AMD (Radiant) study to focus on the spinal cord injury (SCI) trial.
Stem's management announced the decision to focus on the spinal cord injury (SCI) trial. Management will suspend the company's phase II AMD (Radiant)... MoreUPDATE: StemCells (STEM) Declines After Shares Resume Trading
December 23, 2015 8:10 AM EST(Updated - December 23, 2015 8:16 AM EST)
StemCells (NASDAQ: STEM) Declines After Shares Resume Trading
... More


